Polaryx Therapeutics, Inc. AI Stock Analysis
Polaryx Therapeutics, Inc. (PLYX) AI Stock Analysis
Polaryx Therapeutics, Inc.
(NASDAQ:PLYX)
No summary available
Polaryx Therapeutics, Inc. (PLYX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $66.30M
- Dividend Yield
- ―
- Average Volume (3M)
- 36.52K
- Price to Earnings (P/E)
- -7.4
- Beta (1Y)
- 0.35
- Revenue Growth
- ―
- EPS Growth
- -4.21%
- Country
- US
- Employees
- 11
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Polaryx Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which co...
Polaryx Therapeutics, Inc. Risk Analysis
Polaryx Therapeutics, Inc. disclosed 81 risk factors in its most recent earnings report. Polaryx Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksPolaryx Therapeutics, Inc. Peers Comparison
Overall Rating
CUE46Neutral
PEPG44Neutral
CNTB43Neutral
ALDX42Neutral
ATRA38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $37.62M | -0.14 | -931.52% | ― | 401.93% | -115.89% | |
| 44Neutral | $272.20M | -3.07 | -58.18% | ― | ― | 62.59% | |
| 43Neutral | $40.51M | -1.11 | -171.83% | ― | ― | ― | |
| 42Neutral | $43.56M | -2.63 | >-0.01% | ― | ― | 56.04% | |
| 38Underperform | $64.59M | -6.27 | 38.79% | ― | -97.39% | -155.19% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PLYX | Polaryx Therapeutics, Inc. | 1.33 | -33.67 | -96.20% | |
| ALDX | Aldeyra Therapeutics | 0.84 | -4.39 | -83.94% | |
| ATRA | Atara Biotherapeutics Inc | 6.33 | -7.70 | -54.88% | |
| CUE | Cue Biopharma | 4.15 | -13.56 | -76.56% | |
| CNTB | Connect Biopharma Holdings Ltd. | 0.59 | -2.32 | -79.73% | |
| PEPG | PepGen Inc. | 3.78 | -2.01 | -34.72% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
